Verastem Stock Performance
| VSTM Stock | USD 6.09 0.14 2.35% |
On a scale of 0 to 100, Verastem holds a performance score of 7. The entity has a beta of -0.43, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Verastem are expected to decrease at a much lower rate. During the bear market, Verastem is likely to outperform the market. Please check Verastem's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Verastem's existing price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Verastem are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Verastem displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.35 | Five Day Return (3.64) | Year To Date Return (6.16) | Ten Year Return (93.32) | All Time Return (95.42) |
Last Split Factor 1:12 | Last Split Date 2023-06-01 |
1 | Disposition of 3245 shares by Paterson Dan of Verastem at 2.16 subject to Rule 16b-3 | 11/18/2024 |
2 | Disposition of 273 shares by Stuglik Brian M of Verastem at 10.38 subject to Rule 16b-3 | 11/27/2024 |
3 | Disposition of 244 shares by Paterson Dan of Verastem at 4.54 subject to Rule 16b-3 | 12/16/2024 |
4 | Disposition of 183 shares by Paterson Dan of Verastem at 4.37 subject to Rule 16b-3 | 12/19/2024 |
5 | Disposition of tradable shares by Daniel Calkins of Verastem at 3.91 subject to Rule 16b-3 | 12/24/2024 |
6 | Verastem Oncology Announces FDA Acceptance and Priority Review of NDA for Avutometinib and Defactinib | 01/02/2025 |
7 | Disposition of tradable shares by Daniel Calkins of Verastem at 6.94 subject to Rule 16b-3 | 01/06/2025 |
8 | Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 01/08/2025 |
9 | Acquisition by Daniel Calkins of 38800 shares of Verastem subject to Rule 16b-3 | 01/10/2025 |
10 | Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurre... | 01/13/2025 |
11 | Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on... | 01/14/2025 |
12 | Verastem Oncology Names Matthew E. Ros as Chief Operating Officer | 01/15/2025 |
13 | Verastem Appoints Matthew E. Ros as Chief Operating Officer | 01/22/2025 |
14 | Mizuho maintains Verastem stock outperform with 9 target - Investing.com | 01/24/2025 |
15 | Vanguard Group Inc. Increases Stake in Verastem Inc. | 01/31/2025 |
16 | Disposition of 858 shares by Paterson Dan of Verastem at 5.7 subject to Rule 16b-3 | 02/04/2025 |
| Begin Period Cash Flow | 75.8 M |
Verastem |
Verastem Relative Risk vs. Return Landscape
If you would invest 446.00 in Verastem on November 9, 2024 and sell it today you would earn a total of 163.00 from holding Verastem or generate 36.55% return on investment over 90 days. Verastem is currently generating 0.8118% in daily expected returns and assumes 8.0648% risk (volatility on return distribution) over the 90 days horizon. In different words, 71% of stocks are less volatile than Verastem, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Verastem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Verastem's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Verastem, and traders can use it to determine the average amount a Verastem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1007
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VSTM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.06 actual daily | 71 71% of assets are less volatile |
Expected Return
| 0.81 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Verastem is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Verastem by adding it to a well-diversified portfolio.
Verastem Fundamentals Growth
Verastem Stock prices reflect investors' perceptions of the future prospects and financial health of Verastem, and Verastem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Verastem Stock performance.
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (11.45) % | ||||
| Current Valuation | 214.23 M | ||||
| Shares Outstanding | 44.51 M | ||||
| Price To Earning | (3.02) X | ||||
| Price To Book | 23.94 X | ||||
| Price To Sales | 27.10 X | ||||
| Gross Profit | 10 M | ||||
| EBITDA | (83.17 M) | ||||
| Net Income | (87.37 M) | ||||
| Cash And Equivalents | 94.31 M | ||||
| Cash Per Share | 0.50 X | ||||
| Total Debt | 41.56 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 4.87 X | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (86.46 M) | ||||
| Earnings Per Share | (3.14) X | ||||
| Market Capitalization | 271.04 M | ||||
| Total Asset | 149.72 M | ||||
| Retained Earnings | (824.89 M) | ||||
| Working Capital | 117.3 M | ||||
| Current Asset | 110.84 M | ||||
| Current Liabilities | 10.11 M | ||||
About Verastem Performance
By examining Verastem's fundamental ratios, stakeholders can obtain critical insights into Verastem's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Verastem is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -205.3 K | -195.1 K | |
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.86) | (0.90) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | (1.75) | (1.84) |
Things to note about Verastem performance evaluation
Checking the ongoing alerts about Verastem for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Verastem help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Verastem is way too risky over 90 days horizon | |
| Verastem appears to be risky and price may revert if volatility continues | |
| Verastem has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (87.37 M) with profit before overhead, payroll, taxes, and interest of 10 M. | |
| Verastem currently holds about 94.31 M in cash with (86.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Roughly 67.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 858 shares by Paterson Dan of Verastem at 5.7 subject to Rule 16b-3 |
- Analyzing Verastem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Verastem's stock is overvalued or undervalued compared to its peers.
- Examining Verastem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Verastem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Verastem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Verastem's stock. These opinions can provide insight into Verastem's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.